Stem Cell Transplant or Cellular Therapy - Allogeneic

**Allogeneic**

**AML/MDS/ALL**
- IRB# 17622 A Phase 1b Trial for Patients with Advanced Hematologic Malignancies undergoing Allogeneic Hematopoietic Cell Transplantation with TregGraft, a T-cell Depleted Graft with Additional Infusion of Conventional T cells and Regulatory T cells

**AML/Only**
- IRB# 20708 A Multicenter, Phase 1b Trial of Tabetcelucel for Solid Organ or Allogeneic stem cell transplant Subjects with Epstein Barr Virus associated Post Transplant Lymphoproliferative Disease after failure of Rituximab or Rituximab and chemotherapy. All Ages.

**EBV**
- IRB# 2079 A Phase 2 Study of Tabetcelucel for Solid Organ or Allogeneic stem cell transplant Subjects with Epstein Barr Virus associated Post Transplant Lymphoproliferative Disease after failure of Rituximab or Rituximab and chemotherapy. All Ages.

**Severe Aplastic Anemia**
- IRB# 16943 BMT CTN 1702 Clinical Transplant Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation

**Multiple Diseases**
- IRB# 19907 A Phase 1/2 Study of Allogeneic CRISPR engineered T Cells in patients with B cell malignancy

**BMT CTN**
- IRB# 21119 An Open Label Expanded Access Study of Omidubicel, an Allogeneic Transplantation in Patients with Hematological Malignancies

**EBV**
- IRB# 21423 A Phase 1/2 Study of RTX-240 Monotherapy

**B-Cell Malignancies**
- IRB# 21807 Phase 1/2, Double-Blind, Placebo-Controlled, Dose Escalation and Expansion Study of ALVR106 in Addition to Standard of Care for the Treatment of High-Risk Patients with Respiratory Viral Infections After Hematopoietic Stem Cell Transplant.

**Malignancies**
- IRB# 21691 Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR105) for the Treatment of Patients With Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplant.

**Hematopoietic**
- IRB# 21465 A Phase 1/2 Study to Evaluate the Safety and Efficacy of JSP191 in Combination with a Reduced Intensity Conditioning Regimen of Low Dose Radiation and Fludarabine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)

**Multiple Myeloma**
- IRB# 20759 A Phase 1 Dose Escalation and Cohort Expansion Study of Safety and Efficacy of Anti-BCMA Allogeneic CRISPR Cas-9-Engineered T Cells (CTX120) in Subjects with Relapsed or Refractory Multiple Myeloma

**Solid Tumor**
- IRB# 20379 A Phase 2 Study of Omidubicel for Allogeneic stem cell transplant Subjects with Epstein Barr Virus associated Post Transplant Lymphoproliferative Disease after failure of Rituximab or Rituximab and chemotherapy. All Ages.

**Multiple**

Key
- Open for Enrollment
- In Development
- Enrollment on Hold

08/06/2020

http://www.knight.php